Filter Results:
- Full text PDF available (29)
Publication Year
2004
2019
- This year (17)
- Last 5 years (74)
- Last 10 years (104)
Publication Type
Co-author
Journals and Conferences
Learn More
- Jonathan R. Strosberg, Ghassan E El-Haddad, +32 authors Eric Krenning
- The New England journal of medicine
- 2017
BACKGROUND
Patients with advanced midgut neuroendocrine tumors who have had disease progression during first-line somatostatin analogue therapy have limited therapeutic options. This randomized,… (More)
- Victoria Bolós, Joan Manuel Gasent, Sara López-Tarruella, Enrique Grande
- OncoTargets and therapy
- 2010
Focal adhesion kinase (FAK) and steroid receptor coactivator (Src) are intracellular (nonreceptor) tyrosine kinases that physically and functionally interact to promote a variety of cellular… (More)
- Vincenza Conteduca, Daniel Wetterskog, +30 authors Gerhardt Attard
- Annals of oncology : official journal of the…
- 2017
Background
There is an urgent need to identify biomarkers to guide personalized therapy in castration-resistant prostate cancer (CRPC). We aimed to clinically qualify androgen receptor (AR) gene… (More)
- Matthew H. Kulke, Dieter Hoersch, +16 authors Marianne Ellen Pavel
- Journal of clinical oncology : official journal…
- 2017
Purpose Preliminary studies suggested that telotristat ethyl, a tryptophan hydroxylase inhibitor, reduces bowel movement (BM) frequency in patients with carcinoid syndrome. This placebo-controlled… (More)
- J Capdevila, Alfredo Carrato, Josep Tabernero, Enrique Grande
- Critical reviews in oncology/hematology
- 2014
Increasing knowledge of the pro-angiogenic processes involved in the progression of metastatic colorectal cancer (mCRC) has resulted in the clinical development of several anti-angiogenic agents,… (More)
- P Jiménez-Fonseca, A Carmona-Bayonas, +8 authors Enrique Grande
- Cancer and Metastasis Reviews
- 2015
Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are rare neoplasms capable of producing hormones. The development of new treatments has improved progression-free survival, albeit with… (More)
- Miguel Angel MartÃn, Jesús GarcÃa-Donas, +9 authors Eduardo Diaz-Rubio
- Clinical breast cancer
- 2004
Thirty-five patients with metastatic breast cancer (MBC) entered a phase II study of pegylated liposomal doxorubicin 35 mg/m2 intravenously (i.v.) on day 1 plus vinorelbine 30 mg/m2 i.v. on day 1… (More)
- Teresa Alonso-Gordoa, J. I. Raba DÃez, Manuel Gerardo G. Duran, Enrique Grande
- Therapeutic advances in medical oncology
- 2015
Advanced thyroid carcinoma is an infrequent tumor entity with limited treatment possibilities until recently. The extraordinary improvement in the comprehension of genetic and molecular alterations… (More)
- Enrique Grande, Michael C. Kreissl, +7 authors J Capdevila
- Advances in therapy
- 2013
INTRODUCTION
Vandetanib has recently demonstrated clinically meaningful benefits in patients with unresectable, locally advanced or metastatic medullary thyroid cancer (MTC). Given the potential for… (More)
- Enrique Grande, Jaume Capdevila, Jorge Barriuso, Luis Antón-Aparicio, Daniel E. Castellano
- Cancer and Metastasis Reviews
- 2011
Neuroendocrine tumors (NETs) comprise a broad range of neoplasms that share biological and embryological origin. A deeper knowledge in the underlying molecular biology that results in the development… (More)